You are here

Mefloquine Hydrochloride Tablets Approved by FDA

WOODCLIFF LAKE, N.J., Dec. 30 /PRNewswire-FirstCall/ -- Barr Laboratories, Inc. (NYSE: BRL) today announced that it has received approval from the U.S. Food & Drug Administration (FDA) for Mefloquine Hydrochloride Tablets, 250 mg, the generic equivalent of Hoffman LaRoche, Inc.'s Lariam(R) Tablets. The Company plans to launch the product in early January 2004.

Barr's Mefloquine Hydrochloride Tablets are indicated for the prophylaxis of and treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum or by plasmodium vivax. Mefloquine should not be prescribed for prophylaxis in patients with psychiatric disorders or depression, and may cause psychiatric symptoms in some patients. Barr's product will compete in a market that had sales of approximately $38.2 million for the twelve months ended October 2003.

Source: Barr Laboratories, Inc.

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens